Skip to main content
. Author manuscript; available in PMC: 2020 Dec 22.
Published in final edited form as: J Am Coll Cardiol. 2017 Oct 31;70(18):2213–2223. doi: 10.1016/j.jacc.2017.09.011

Figure 2. Cumulative incidence of myocardial infarction or stent thrombosis (Panel A), major adverse cardiovascular or cerebrovascular events (MACCE) (Panel B), and GUSTO moderate/severe bleeding (Panel C) from 12–30 months after randomization, according to randomization group in subjects with and without anatomically complex lesions.

Figure 2.

Figure 2.

Consistency in treatment effect of continued thienopyridine was observed in subjects with and without anatomically complex lesions in the 12–30 month time period for all major endpoints.